Aethlon Medical Reports Cash Balance of Approximately $7M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy AEMD?
As of December 31, 2025, Aethlon had a cash balance of approximately $7M. "We remain committed to advancing our clinical programs and research initiatives with operational discipline," said James Frakes, CEO and CFO of Aethlon Medical. "Recent progress in our trials, research collaborations, and technology development continues to move us closer to delivering therapeutic solutions for cancer and life-threatening infectious diseases."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AEMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AEMD
About AEMD
Aethlon Medical, Inc. is a clinical-stage medical device company. The Company is focused on advancing the Hemopurifier (HP), a clinical-stage immunotherapeutic device intended for applications in cancer, life-threatening viral infections, and organ transplantation and other areas of significant unmet needs. In pre-clinical studies, the Hemopurifier has exhibited the capacity to remove harmful extracellular vesicles (EVs) and enveloped viruses from biological fluids, utilizing its proprietary lectin-based mechanism. These extracellular vesicles have been implicated in disease processes such as immune suppression and metastasis in cancer as well as in the progression of severe life-threatening infectious diseases. The United States Food and Drug Administration (FDA) has designated the Hemopurifier as a Breakthrough Device for the treatment of individuals with advanced or metastatic cancer who are unresponsive to or intolerant of standard of care therapy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aethlon Medical Reports Q3 2026 Earnings and Trial Progress
- Clinical Trial Progress: Aethlon Medical has completed two Hemopurifier treatments in its Australian oncology trial's second cohort, with a third patient scheduled for treatment by the end of February, demonstrating the company's ongoing commitment to clinical advancement that may pave the way for future therapeutic options.
- Financial Update: As of December 31, 2025, the company reported a cash balance of approximately $7 million, and while the operating loss for the quarter increased to $2.06 million, operating expenses for the nine-month period decreased by 27% compared to last year, reflecting effective cost control measures.
- Recruitment Strategy Optimization: Management highlighted an increase in potential trial participants due to new recruitment strategies, which is expected to accelerate the advancement to Cohort 3, thereby enhancing the Hemopurifier's application potential in oncology and infusion centers.
- Future Outlook: The management plans to conduct a Data Safety Monitoring Board review in late March to determine whether to advance to Cohort 3, indicating the company's confidence in its clinical trials and a positive outlook for future growth.
See More
Aethlon Medical Reports Q3 Loss, Cash Reserves Decline
- Earnings Miss: Aethlon Medical reported a Q3 GAAP EPS of -$2.45, missing estimates by $0.03, indicating ongoing challenges in profitability that could undermine investor confidence.
- Cash Reserves Pressure: As of December 31, 2025, Aethlon's cash balance stood at approximately $7.0 million, reflecting liquidity pressures that may limit future R&D and operational activities.
- Rising Operating Expenses: Consolidated operating expenses for Q3 2025 were approximately $2.06 million, up $250,000 or 13.6% from $1.81 million in the same period of 2024, suggesting challenges in cost control that could impact overall financial health.
- Market Reaction Outlook: Given the disappointing earnings report, investors may adopt a cautious stance on Aethlon's future prospects, particularly as the company requires additional funding to support its R&D projects, potentially leading to stock price volatility.
See More
Aethlon Medical Reports Q3 Financial Results and Clinical Progress
- Clinical Trial Progress: Aethlon is actively enrolling and treating participants in Cohort 2 of its Australian oncology trial, building on favorable improvements in extracellular vesicle and immune cell counts from Cohort 1, indicating the safety and tolerability of Hemopurifier treatments and laying the groundwork for future therapeutic options.
- Technology Development Collaboration: Under a Material Transfer Agreement, Stavro is evaluating the compatibility of the Hemopurifier with its simplified blood treatment platform, which may support the use of Hemopurifier in oncology units and infusion centers, reducing reliance on large dialysis catheters and machines.
- Financial Performance: As of December 31, 2025, Aethlon reported a cash balance of approximately $7 million; despite a 13.6% increase in operating expenses to $2.06 million compared to the prior year, overall operating expenses decreased by 26.9% over the nine months of 2025, reflecting the company's cost optimization efforts.
- Future Outlook: Aethlon's CEO emphasized the company's commitment to advancing clinical programs and research initiatives, stating that despite financial challenges, ongoing technological advancements and collaborative research are moving Aethlon closer to delivering therapeutic solutions for cancer and life-threatening infectious diseases.
See More
Aethlon Medical to Announce Q3 Earnings on February 11
- Earnings Announcement Date: Aethlon Medical (AEMD) is set to release its Q3 earnings on February 11 after market close, with a consensus EPS estimate of -$2.01, reflecting a staggering 1446.2% year-over-year decline, indicating significant financial challenges ahead.
- Earnings Expectations Analysis: Over the past two years, AEMD has only beaten EPS estimates 50% of the time and revenue estimates 13% of the time, highlighting ongoing difficulties in profitability and revenue growth that may impact investor confidence.
- Estimate Revision Status: In the last three months, there has been one upward revision to EPS estimates with no downward adjustments, suggesting a slight optimism in market expectations, although the overall outlook remains low, potentially leading to stock price volatility.
- Quant Rating Insight: Seeking Alpha's Quant Rating on Aethlon Medical reflects market concerns regarding its financial health, prompting investors to closely monitor the upcoming earnings report to assess the company's future growth potential and investment value.
See More
Aethlon Medical Schedules Q3 Financial Results Conference Call
- Financial Results Announcement: Aethlon Medical will release its fiscal third-quarter financial results for the period ending December 31, 2025, on February 12, 2026, at 4:15 p.m. ET, highlighting advancements in cancer and life-threatening infectious disease treatments.
- Conference Call Details: Management will host a conference call on the same day at 4:30 p.m. ET to review financial results and recent corporate developments, followed by a Q&A session to enhance interaction between investors and management.
- Registration Process: Interested parties can register via a provided link to receive dial-in numbers, while those unable to pre-register can call the toll-free number 1-844-836-8741 or the international number 1-412-317-5442 to ensure participation in the call.
- Hemopurifier Device Overview: Aethlon's Hemopurifier is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections, having received FDA Breakthrough Device designation, demonstrating potential in treating patients with refractory cancer.
See More
Aethlon Medical Secures $3.3 Million Financing to Accelerate Cancer Treatment
- Financing Agreement: Aethlon Medical has entered into a securities purchase agreement with a single institutional investor to sell 595,897 shares and warrants for 1,042,820 shares, raising approximately $3.3 million, expected to close on December 8, 2025, enhancing liquidity for R&D support.
- Warrant Inducement: The company has negotiated a warrant inducement agreement to lower the exercise price of March and September 2025 warrants to $4.03, which is expected to encourage the investor to exercise these warrants, providing additional funding for the company.
- Market Compliance: This financing adheres to Nasdaq rules under Section 4(a)(2) of the Securities Act, ensuring the company's compliance in capital markets, which enhances investor confidence and improves the company's reputation.
- Future Growth Potential: Aethlon is focused on developing the Hemopurifier to address unmet needs in oncology and infectious diseases, and this financing will accelerate clinical trial processes, boosting the company's competitiveness in the medical device sector.
See More
Aethlon Medical Reports Q3 2026 Earnings and Trial Progress
- Clinical Trial Progress: Aethlon Medical has completed two Hemopurifier treatments in its Australian oncology trial's second cohort, with a third patient scheduled for treatment by the end of February, demonstrating the company's ongoing commitment to clinical advancement that may pave the way for future therapeutic options.
- Financial Update: As of December 31, 2025, the company reported a cash balance of approximately $7 million, and while the operating loss for the quarter increased to $2.06 million, operating expenses for the nine-month period decreased by 27% compared to last year, reflecting effective cost control measures.
- Recruitment Strategy Optimization: Management highlighted an increase in potential trial participants due to new recruitment strategies, which is expected to accelerate the advancement to Cohort 3, thereby enhancing the Hemopurifier's application potential in oncology and infusion centers.
- Future Outlook: The management plans to conduct a Data Safety Monitoring Board review in late March to determine whether to advance to Cohort 3, indicating the company's confidence in its clinical trials and a positive outlook for future growth.
See More
Aethlon Medical Reports Q3 Loss, Cash Reserves Decline
- Earnings Miss: Aethlon Medical reported a Q3 GAAP EPS of -$2.45, missing estimates by $0.03, indicating ongoing challenges in profitability that could undermine investor confidence.
- Cash Reserves Pressure: As of December 31, 2025, Aethlon's cash balance stood at approximately $7.0 million, reflecting liquidity pressures that may limit future R&D and operational activities.
- Rising Operating Expenses: Consolidated operating expenses for Q3 2025 were approximately $2.06 million, up $250,000 or 13.6% from $1.81 million in the same period of 2024, suggesting challenges in cost control that could impact overall financial health.
- Market Reaction Outlook: Given the disappointing earnings report, investors may adopt a cautious stance on Aethlon's future prospects, particularly as the company requires additional funding to support its R&D projects, potentially leading to stock price volatility.
See More
Aethlon Medical Reports Q3 Financial Results and Clinical Progress
- Clinical Trial Progress: Aethlon is actively enrolling and treating participants in Cohort 2 of its Australian oncology trial, building on favorable improvements in extracellular vesicle and immune cell counts from Cohort 1, indicating the safety and tolerability of Hemopurifier treatments and laying the groundwork for future therapeutic options.
- Technology Development Collaboration: Under a Material Transfer Agreement, Stavro is evaluating the compatibility of the Hemopurifier with its simplified blood treatment platform, which may support the use of Hemopurifier in oncology units and infusion centers, reducing reliance on large dialysis catheters and machines.
- Financial Performance: As of December 31, 2025, Aethlon reported a cash balance of approximately $7 million; despite a 13.6% increase in operating expenses to $2.06 million compared to the prior year, overall operating expenses decreased by 26.9% over the nine months of 2025, reflecting the company's cost optimization efforts.
- Future Outlook: Aethlon's CEO emphasized the company's commitment to advancing clinical programs and research initiatives, stating that despite financial challenges, ongoing technological advancements and collaborative research are moving Aethlon closer to delivering therapeutic solutions for cancer and life-threatening infectious diseases.
See More
Aethlon Medical to Announce Q3 Earnings on February 11
- Earnings Announcement Date: Aethlon Medical (AEMD) is set to release its Q3 earnings on February 11 after market close, with a consensus EPS estimate of -$2.01, reflecting a staggering 1446.2% year-over-year decline, indicating significant financial challenges ahead.
- Earnings Expectations Analysis: Over the past two years, AEMD has only beaten EPS estimates 50% of the time and revenue estimates 13% of the time, highlighting ongoing difficulties in profitability and revenue growth that may impact investor confidence.
- Estimate Revision Status: In the last three months, there has been one upward revision to EPS estimates with no downward adjustments, suggesting a slight optimism in market expectations, although the overall outlook remains low, potentially leading to stock price volatility.
- Quant Rating Insight: Seeking Alpha's Quant Rating on Aethlon Medical reflects market concerns regarding its financial health, prompting investors to closely monitor the upcoming earnings report to assess the company's future growth potential and investment value.
See More
Aethlon Medical Schedules Q3 Financial Results Conference Call
- Financial Results Announcement: Aethlon Medical will release its fiscal third-quarter financial results for the period ending December 31, 2025, on February 12, 2026, at 4:15 p.m. ET, highlighting advancements in cancer and life-threatening infectious disease treatments.
- Conference Call Details: Management will host a conference call on the same day at 4:30 p.m. ET to review financial results and recent corporate developments, followed by a Q&A session to enhance interaction between investors and management.
- Registration Process: Interested parties can register via a provided link to receive dial-in numbers, while those unable to pre-register can call the toll-free number 1-844-836-8741 or the international number 1-412-317-5442 to ensure participation in the call.
- Hemopurifier Device Overview: Aethlon's Hemopurifier is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections, having received FDA Breakthrough Device designation, demonstrating potential in treating patients with refractory cancer.
See More
Aethlon Medical Secures $3.3 Million Financing to Accelerate Cancer Treatment
- Financing Agreement: Aethlon Medical has entered into a securities purchase agreement with a single institutional investor to sell 595,897 shares and warrants for 1,042,820 shares, raising approximately $3.3 million, expected to close on December 8, 2025, enhancing liquidity for R&D support.
- Warrant Inducement: The company has negotiated a warrant inducement agreement to lower the exercise price of March and September 2025 warrants to $4.03, which is expected to encourage the investor to exercise these warrants, providing additional funding for the company.
- Market Compliance: This financing adheres to Nasdaq rules under Section 4(a)(2) of the Securities Act, ensuring the company's compliance in capital markets, which enhances investor confidence and improves the company's reputation.
- Future Growth Potential: Aethlon is focused on developing the Hemopurifier to address unmet needs in oncology and infectious diseases, and this financing will accelerate clinical trial processes, boosting the company's competitiveness in the medical device sector.
See More
